PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32722075-8 2020 In addition, LY and TAM combination induced the apoptotic genes Caspase-3, Caspase-7, and p53, as well as p21 as cell cycle promotor, and significantly downregulated the anti-apoptotic genes Bcl-2 and survivin. Tamoxifen 20-23 tumor protein p53 Homo sapiens 90-93 32987137-7 2020 Conversely, the sensitivity of GCN5-AIB1-overexpressing MCF7 cells to tamoxifen was restored by forced p53 expression. Tamoxifen 70-79 tumor protein p53 Homo sapiens 103-106 33177647-4 2020 Coffee decoction cooperated with tamoxifen to induce cell-cycle arrest and apoptotic cell death, which may have been mediated by decreases in cyclin D1 expression and the activation of p53 tumor suppressor. Tamoxifen 33-42 tumor protein p53 Homo sapiens 185-188 33177647-6 2020 The activation of p53 through the cooperative effects of these unidentified component(s), caffeine, and tamoxifen appeared to be due to the suppression of the ERK and Akt pathways. Tamoxifen 104-113 tumor protein p53 Homo sapiens 18-21 33177647-7 2020 Although the mechanisms by which the suppression of these pathways induces p53-mediated apoptotic cell death remain unclear, the combination of decaffeinated coffee, caffeine, and tamoxifen also caused cell-cycle arrest and apoptotic cell death, suggesting that unknown compound(s) present in decaffeinated coffee cooperate with caffeine and tamoxifen. Tamoxifen 180-189 tumor protein p53 Homo sapiens 75-78 30990221-10 2019 Tamoxifen increased ESR2-mutant TP53 interaction leading to reactivation of TP73 and apoptosis. Tamoxifen 0-9 tumor protein p53 Homo sapiens 32-36 30990221-13 2019 Our study suggests that ESR2-mutant TP53 combination prognosticates survival in TNBC revealing a novel strategy to stratify TNBC for therapeutic intervention potentially by repurposing tamoxifen. Tamoxifen 185-194 tumor protein p53 Homo sapiens 36-40 30535478-0 2019 TP53 upregulates alpha-smooth muscle actin expression in tamoxifen-resistant breast cancer cells. Tamoxifen 57-66 tumor protein p53 Homo sapiens 0-4 30504836-6 2018 CXCR4 upregulation in radioresistant tumour ECs was highly associated with SDF-1+ TAM recruitment and M2 polarization of TAMs, which was suppressed by Trp53 deletion. Tamoxifen 121-125 tumor protein p53 Homo sapiens 151-156 29464864-8 2018 A further case study in breast invasive carcinoma (BRCA) found that DRCE expression was consistent with the drug response pattern and the aberrant expression of the two NEAT1-related DRCEs may lead to poor response to tamoxifen therapy for patients with TP53 mutations. Tamoxifen 218-227 tumor protein p53 Homo sapiens 254-258 30285883-7 2018 Testing this, we found that estrogen receptor-positive, TP53 wild-type breast cancer cells that were made senescent by doxorubicin treatment were sensitive to tamoxifen. Tamoxifen 159-168 tumor protein p53 Homo sapiens 56-60 30050469-9 2018 Of the 2,713 genes that were significantly upregulated following a 48 h incubation with 250 muM tamoxifen, most were categorized as either growth-related or pro-apoptotic intermediates that fit into the Tp53 and/or MAPK signaling pathways. Tamoxifen 96-105 tumor protein p53 Homo sapiens 203-207 30050469-10 2018 Collectively, our results display that the effects of tamoxifen on the breast cancer MCF-7 cell line are mediated by the activation of important signaling pathways including Tp53 and MAPKs to induce apoptosis. Tamoxifen 54-63 tumor protein p53 Homo sapiens 174-178 26909605-8 2016 Furthermore, in cell culture models, ERalpha positively regulates MDM4 and MDM2 expression via p53-independent mechanisms, and these effects can be blocked by the clinically-relevant endocrine therapies fulvestrant and tamoxifen. Tamoxifen 219-228 tumor protein p53 Homo sapiens 95-98 29590203-0 2018 Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells. Tamoxifen 70-79 tumor protein p53 Homo sapiens 130-133 27888811-3 2017 Overexpression of mutated p53 with reduced or abolished function is often connected to resistance to standard medications, including cisplatin, alkylating agents (temozolomide), anthracyclines, (doxorubicin), antimetabolites (gemcitabine), antiestrogenes (tamoxifen) and EGFR-inhibitors (cetuximab). Tamoxifen 256-265 tumor protein p53 Homo sapiens 26-29 25595558-7 2015 Consistent with this observation in SK-MEL28 cells, Sp1 was necessary for the tamoxifen-regulated Raf-1:ER to induce p21(CIP1) transcription in U251 cells, in which TP53 is mutated. Tamoxifen 78-87 tumor protein p53 Homo sapiens 166-170 26365581-11 2015 Synergistic effect with tamoxifen was observed in terms of increased p53 protein level. Tamoxifen 24-33 tumor protein p53 Homo sapiens 69-72 25503558-4 2015 Here, we report that after systemic injection of tamoxifen, the vast majority of Pax7-expressing cells remain quiescent despite mutation of p53 and Kras. Tamoxifen 49-58 tumor protein p53 Homo sapiens 140-143 24853176-0 2014 MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases. Tamoxifen 69-78 tumor protein p53 Homo sapiens 51-55 23077249-6 2012 Interestingly, both ER agonists such as estradiol and the selective ER modulator (SERM) tamoxifen promote p53 antagonism. Tamoxifen 88-97 tumor protein p53 Homo sapiens 106-109 24361399-14 2014 SIGNIFICANCE: These results demonstrate that tamoxifen promotes senescence through a ROS-p53-p21(Cip1/WAF1) dependent pathway by inhibiting CK2 activity in breast cancer and colon cancer cells. Tamoxifen 45-54 tumor protein p53 Homo sapiens 89-92 24361399-13 2014 Finally, experiments using T47D (wild-type p53) and MDA-MB-435 (mutant p53) cell lines suggested that tamoxifen induces p53-independent ROS production as well as p53-dependent senescence in breast cancer cells. Tamoxifen 102-111 tumor protein p53 Homo sapiens 43-46 24361399-13 2014 Finally, experiments using T47D (wild-type p53) and MDA-MB-435 (mutant p53) cell lines suggested that tamoxifen induces p53-independent ROS production as well as p53-dependent senescence in breast cancer cells. Tamoxifen 102-111 tumor protein p53 Homo sapiens 71-74 24361399-13 2014 Finally, experiments using T47D (wild-type p53) and MDA-MB-435 (mutant p53) cell lines suggested that tamoxifen induces p53-independent ROS production as well as p53-dependent senescence in breast cancer cells. Tamoxifen 102-111 tumor protein p53 Homo sapiens 71-74 24361399-13 2014 Finally, experiments using T47D (wild-type p53) and MDA-MB-435 (mutant p53) cell lines suggested that tamoxifen induces p53-independent ROS production as well as p53-dependent senescence in breast cancer cells. Tamoxifen 102-111 tumor protein p53 Homo sapiens 71-74 30780881-7 2011 A recent article explored the role of the tumor-suppressor gene TP53 in the response of breast cancer cell lines to tamoxifen and the pure anti-estrogen, fulvestrant. Tamoxifen 116-125 tumor protein p53 Homo sapiens 64-68 21191649-0 2011 P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Tamoxifen 51-60 tumor protein p53 Homo sapiens 0-3 21191649-9 2011 These data demonstrate that p53 regulates ER expression in vivo, and affects response to tamoxifen. Tamoxifen 89-98 tumor protein p53 Homo sapiens 28-31 22041887-8 2011 In coculture, tamoxifen induces the upregulation of TIGAR (TP53-induced glycolysis and apoptosis regulator), a p53 regulated gene that simultaneously inhibits glycolysis, autophagy and apoptosis and reduces ROS generation, thereby promoting oxidative mitochondrial metabolism. Tamoxifen 14-23 tumor protein p53 Homo sapiens 111-114 21119367-1 2010 This study was undertaken to investigate the expression of p53, Ki-67, and CD31 proteins in endometrial polyps of postmenopausal women treated with tamoxifen (TAM). Tamoxifen 148-157 tumor protein p53 Homo sapiens 59-62 21547354-9 2011 Although there were no significant differences in PTEN, hMLH1 and hMSH2 expression between the two groups, p53 mutation was more frequent in three out of five cases (60%) in the TAM group compared with 2 of 15 cases in the EMC group (13.3%). Tamoxifen 178-181 tumor protein p53 Homo sapiens 107-110 20549698-0 2011 p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. Tamoxifen 34-43 tumor protein p53 Homo sapiens 0-3 21119367-1 2010 This study was undertaken to investigate the expression of p53, Ki-67, and CD31 proteins in endometrial polyps of postmenopausal women treated with tamoxifen (TAM). Tamoxifen 159-162 tumor protein p53 Homo sapiens 59-62 19460356-0 2009 Antiproliferation and apoptosis induced by tamoxifen in human bile duct carcinoma QBC939 cells via upregulated p53 expression. Tamoxifen 43-52 tumor protein p53 Homo sapiens 111-114 20696891-10 2010 Furthermore, retrospective studies analyzing response to tamoxifen therapy in a subset of patients with ER-positive breast cancer expressing either wild-type or mutant p53 suggest that the presence of wild-type p53 is an important determinant of positive therapeutic response. Tamoxifen 57-66 tumor protein p53 Homo sapiens 168-171 20696891-10 2010 Furthermore, retrospective studies analyzing response to tamoxifen therapy in a subset of patients with ER-positive breast cancer expressing either wild-type or mutant p53 suggest that the presence of wild-type p53 is an important determinant of positive therapeutic response. Tamoxifen 57-66 tumor protein p53 Homo sapiens 211-214 19806450-0 2010 Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy. Tamoxifen 109-118 tumor protein p53 Homo sapiens 18-21 19806450-8 2010 The p53-overexpressing patients with breast cancer between 35 and 50 years of age who received tamoxifen following chemotherapy had the greatest adverse effect on outcome. Tamoxifen 95-104 tumor protein p53 Homo sapiens 4-7 19806450-9 2010 Overexpression of p53 is significantly associated with tamoxifen resistance in premenopausal women with breast cancer. Tamoxifen 55-64 tumor protein p53 Homo sapiens 18-21 19460356-5 2009 Increased expression of p53 was observed in TAM-treated cells, indicating that p53 might play an important role in TAM-induced apoptosis in QBC939 cells. Tamoxifen 44-47 tumor protein p53 Homo sapiens 24-27 19460356-5 2009 Increased expression of p53 was observed in TAM-treated cells, indicating that p53 might play an important role in TAM-induced apoptosis in QBC939 cells. Tamoxifen 44-47 tumor protein p53 Homo sapiens 79-82 19460356-5 2009 Increased expression of p53 was observed in TAM-treated cells, indicating that p53 might play an important role in TAM-induced apoptosis in QBC939 cells. Tamoxifen 115-118 tumor protein p53 Homo sapiens 24-27 19460356-5 2009 Increased expression of p53 was observed in TAM-treated cells, indicating that p53 might play an important role in TAM-induced apoptosis in QBC939 cells. Tamoxifen 115-118 tumor protein p53 Homo sapiens 79-82 19351845-3 2009 Previously, we found that p53 genotype was correlated with ER expression and response to tamoxifen in mammary tumors arising in mouse mammary tumor virus-Wnt-1 transgenic mice. Tamoxifen 89-98 tumor protein p53 Homo sapiens 26-29 18425390-0 2008 Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma. Tamoxifen 42-51 tumor protein p53 Homo sapiens 29-32 18397472-6 2008 Immunoblotting revealed that the levels of p53 and p21(WAF1/CIP1) in TAM-treated cells increased in a time- and dose-dependent manner, whereas those of p27(KIP1) and p16 slightly increased or remained unchanged. Tamoxifen 69-72 tumor protein p53 Homo sapiens 43-46 18397472-8 2008 These results suggest that the tumorigenic effect of TAM on MCF-7 cells arises through antitumor effects that are due to the expression of cyclin-dependent kinase inhibitors, especially p21(WAF1/CIP1) and these are regulated by the decrease of wild-type p53. Tamoxifen 53-56 tumor protein p53 Homo sapiens 254-257 18425390-3 2008 The median duration of TAM exposure was significantly longer in patients with p53 mutations than those without p53 mutations (62 vs. 30 months, p=0.028). Tamoxifen 23-26 tumor protein p53 Homo sapiens 78-81 18377724-6 2008 CAS overexpression enhanced p53 accumulation induced by doxorubicin, 5-fluorouracil, cisplatin, tamoxifen, and etoposide. Tamoxifen 96-105 tumor protein p53 Homo sapiens 28-31 18425390-3 2008 The median duration of TAM exposure was significantly longer in patients with p53 mutations than those without p53 mutations (62 vs. 30 months, p=0.028). Tamoxifen 23-26 tumor protein p53 Homo sapiens 111-114 18425390-4 2008 Our observation suggests that prolonged TAM exposure may directly inactivate the p53 gene by acting as a mutagen in a significant fraction of TAM-associated endometrial carcinomas. Tamoxifen 40-43 tumor protein p53 Homo sapiens 81-84 18425390-4 2008 Our observation suggests that prolonged TAM exposure may directly inactivate the p53 gene by acting as a mutagen in a significant fraction of TAM-associated endometrial carcinomas. Tamoxifen 142-145 tumor protein p53 Homo sapiens 81-84 18497060-5 2008 Here, we show that both tamoxifen (Tam) and three-dimensional prepared extracellular matrix culture (3-D rECM) induce apoptosis in HMEC cells with acute loss of p53 [*p53(-) HMECs] through induction of interferon regulatory factor-1 (IRF-1). Tamoxifen 24-33 tumor protein p53 Homo sapiens 161-164 17307334-4 2007 In this study, we found that TAM treatment of MDA-MB-361 breast cancer cells activated p21Waf1/Cip1 gene transcription independently of p53. Tamoxifen 29-32 tumor protein p53 Homo sapiens 136-139 18497060-5 2008 Here, we show that both tamoxifen (Tam) and three-dimensional prepared extracellular matrix culture (3-D rECM) induce apoptosis in HMEC cells with acute loss of p53 [*p53(-) HMECs] through induction of interferon regulatory factor-1 (IRF-1). Tamoxifen 24-33 tumor protein p53 Homo sapiens 167-170 18497060-5 2008 Here, we show that both tamoxifen (Tam) and three-dimensional prepared extracellular matrix culture (3-D rECM) induce apoptosis in HMEC cells with acute loss of p53 [*p53(-) HMECs] through induction of interferon regulatory factor-1 (IRF-1). Tamoxifen 35-38 tumor protein p53 Homo sapiens 161-164 18497060-5 2008 Here, we show that both tamoxifen (Tam) and three-dimensional prepared extracellular matrix culture (3-D rECM) induce apoptosis in HMEC cells with acute loss of p53 [*p53(-) HMECs] through induction of interferon regulatory factor-1 (IRF-1). Tamoxifen 35-38 tumor protein p53 Homo sapiens 167-170 17786323-8 2007 Expression of Her2 or p53 was a significant prognostic indicator in the tamoxifen alone group. Tamoxifen 72-81 tumor protein p53 Homo sapiens 22-25 20020938-4 2008 Our studies showed that CAS over-expression increased p53 accumulation and apoptosis induced by 5-fluorouracil, doxorubicin, cisplatin, and tamoxifen in HT-29 cancer cells. Tamoxifen 140-149 tumor protein p53 Homo sapiens 54-57 16609366-9 2006 CONCLUSION: The present report indicates that the codon 72 polymorphism in the p53 gene may be a predictor of tamoxifen response, suggesting that breast cancer patients lacking the Pro72 allele might be candidates for other therapies. Tamoxifen 110-119 tumor protein p53 Homo sapiens 79-82 17235397-5 2007 Systemic administration of tamoxifen led to p53 activation and tumor regression followed by tumor recurrence. Tamoxifen 27-36 tumor protein p53 Homo sapiens 44-47 17663174-1 2007 The study was concerned with identification of predictive value of p53 expression on sensitivity to tamoxifen in breast cancer management. Tamoxifen 100-109 tumor protein p53 Homo sapiens 67-70 17663174-2 2007 Estrogen receptor-positive cell line MCF-7 was used to establish p53 expression influence on the rate of cell proliferation after tamoxifen. Tamoxifen 130-139 tumor protein p53 Homo sapiens 65-68 15938631-0 2005 Investigating DNA adduct-targeted mutagenicity of tamoxifen: preferential formation of tamoxifen-DNA adducts in the human p53 gene in SV40 immortalized hepatocytes but not endometrial carcinoma cells. Tamoxifen 50-59 tumor protein p53 Homo sapiens 122-125 18603889-0 2006 Evaluation of endometrial changes and p53 expression in tamoxifen treated women: comparison of various methods. Tamoxifen 56-65 tumor protein p53 Homo sapiens 38-41 15938631-0 2005 Investigating DNA adduct-targeted mutagenicity of tamoxifen: preferential formation of tamoxifen-DNA adducts in the human p53 gene in SV40 immortalized hepatocytes but not endometrial carcinoma cells. Tamoxifen 87-96 tumor protein p53 Homo sapiens 122-125 12530022-2 2002 Our previous work suggested tamoxifen-associated endometrial cancers might be associated with p53 mutations. Tamoxifen 28-37 tumor protein p53 Homo sapiens 94-97 12376463-5 2002 Tamoxifen induced growth suppression was independent of p53 status but resulted in up-regulation of cyclin dependent kinase inhibitors (CDKIs) p21/Waf-1, p27/Kip1 and p15/INK4a. Tamoxifen 0-9 tumor protein p53 Homo sapiens 56-59 15832264-9 2005 We also showed that a parallel determination of ER, PgR and p53 expression may carry high predictive value as to response to tamoxifen treatment. Tamoxifen 125-134 tumor protein p53 Homo sapiens 60-63 14633737-9 2003 Treatment with Let, Tam, or E2W resulted in a dose- and time-dependent increase in active caspase-7 and up-regulation of p53 and p21 protein. Tamoxifen 20-23 tumor protein p53 Homo sapiens 121-124 12684392-0 2003 Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Tamoxifen 86-95 tumor protein p53 Homo sapiens 48-52 12684392-5 2003 RESULTS: In univariate analysis, both TP53 gene mutation (28% of the tumors) and a VEGF level above the median value were significantly associated with a short progression-free survival, post-relapse overall survival, and a poor rate of response to tamoxifen. Tamoxifen 249-258 tumor protein p53 Homo sapiens 38-42 12684392-6 2003 In Cox multivariate regression analysis including the traditional predictive factors, the addition of TP53 gene mutation and VEGF status, alone or in combination, significantly predicted a poor efficacy of tamoxifen treatment. Tamoxifen 206-215 tumor protein p53 Homo sapiens 102-106 12684392-9 2003 CONCLUSIONS: Combined TP53 gene mutation status and high VEGF levels of ER-positive primary breast tumors independently predict a poor course of the disease of patients with advanced breast cancer treated with tamoxifen. Tamoxifen 210-219 tumor protein p53 Homo sapiens 22-26 11094056-0 2001 Tamoxifen but not 4-hydroxytamoxifen initiates apoptosis in p53(-) normal human mammary epithelial cells by inducing mitochondrial depolarization. Tamoxifen 0-9 tumor protein p53 Homo sapiens 60-63 12088100-2 2002 Following tamoxifen treatment expression of HER-2 and p53 decreased but Bcl2 remained unchanged. Tamoxifen 10-19 tumor protein p53 Homo sapiens 54-57 11454885-2 2001 HER2, epidermal growth factor receptor (EGFR), and p53 have all been suggested as possible markers of tamoxifen resistance. Tamoxifen 102-111 tumor protein p53 Homo sapiens 51-54 11454885-3 2001 The aim of this study was to investigate interactions between adjuvant treatment with tamoxifen and the content of EGFR, HER2, and p53 in steroid receptor-positive patients. Tamoxifen 86-95 tumor protein p53 Homo sapiens 131-134 11454885-9 2001 Patients with steroid receptor-positive tumors and positive immunohistochemical staining for HER2, EGFR or p53 benefited from treatment with tamoxifen for 1 year, although the latter variable contained independent prognostic information by itself. Tamoxifen 141-150 tumor protein p53 Homo sapiens 107-110 12088100-0 2002 Changes in apoptosis, mitosis, Her-2, p53 and Bcl2 expression in breast carcinomas after short-term tamoxifen treatment. Tamoxifen 100-109 tumor protein p53 Homo sapiens 38-41 11094056-3 2001 We developed an in vitro model of early breast cancer prevention to investigate how tamoxifen and 4-hydroxytamoxifen may act in normal human mammary epithelial cells (HMECs) that have acutely lost p53 function. Tamoxifen 84-93 tumor protein p53 Homo sapiens 197-200 11094056-5 2001 Tamoxifen, but not 4-hydroxytamoxifen, rapidly induced apoptosis in p53(-) HMEC-E6 cells as evidenced by characteristic morphologic changes, annexin V binding, and DNA fragmentation. Tamoxifen 0-9 tumor protein p53 Homo sapiens 68-71 11094056-6 2001 We observed that a decrease in mitochondrial membrane potential, mitochondrial condensation, and caspase activation preceded the morphologic appearance of apoptosis in tamoxifen-treated early passage p53(-) HMEC-E6 cells. Tamoxifen 168-177 tumor protein p53 Homo sapiens 200-203 11094056-7 2001 p53(-) HMEC-E6 cells rapidly developed resistance to tamoxifen-mediated apoptosis within 10 passages in vitro. Tamoxifen 53-62 tumor protein p53 Homo sapiens 0-3 11094056-8 2001 Resistance to tamoxifen in late passage p53(-) HMEC-E6 cells correlated with an increase in mitochondrial mass and a lack of mitochondrial depolarization and caspase activation following tamoxifen treatment. Tamoxifen 14-23 tumor protein p53 Homo sapiens 40-43 9891537-6 1998 P53 was overexpressed in 73% of tamoxifen users compared to 53% of non-users. Tamoxifen 32-41 tumor protein p53 Homo sapiens 0-3 10786679-5 2000 TP53 mutation was significantly associated with a poor response to tamoxifen [31% versus 66%; odds ratio (OR), 0.22; 95% confidence interval (CI), 0.12-0.42; P < 0.0001]. Tamoxifen 67-76 tumor protein p53 Homo sapiens 0-4 10786679-6 2000 Patients with TP53 gene mutations in codons that directly contact DNA or with mutations in the zinc-binding domain loop L3 showed the lowest response to tamoxifen (18% and 15% response rates, respectively). Tamoxifen 153-162 tumor protein p53 Homo sapiens 14-18 10786679-8 2000 In multivariate analysis for response including the classical parameters age and menopausal status, disease-free interval, dominant site of relapse, and levels of estrogen receptor and progesterone receptor, TP53 mutation was a significant predictor of poor response in the tamoxifen-treated group (OR, 0.29; 95% CI, 0.13-0.63; P = 0.0014). Tamoxifen 274-283 tumor protein p53 Homo sapiens 208-212 10786679-10 2000 Interestingly, the response of patients with TP53 mutations to chemotherapy after tamoxifen was not worse than that of patients without these mutations (50% versus 42%; OR, 1.35, nonsignificant). Tamoxifen 82-91 tumor protein p53 Homo sapiens 45-49 10786679-11 2000 The median progression-free survival after systemic treatment was shorter for patients with a TP53 mutation than for patients with wild-type TP53 (6.6 and 0.6 months less for tamoxifen and up-front chemotherapy, respectively). Tamoxifen 175-184 tumor protein p53 Homo sapiens 94-98 10786679-12 2000 In conclusion, TP53 gene mutation of the primary tumor is helpful in predicting the response of patients with metastatic breast disease to tamoxifen therapy. Tamoxifen 139-148 tumor protein p53 Homo sapiens 15-19 11212259-0 2001 Human papillomavirus type 16 E6 inactivation of p53 in normal human mammary epithelial cells promotes tamoxifen-mediated apoptosis. Tamoxifen 102-111 tumor protein p53 Homo sapiens 48-51 11212259-4 2001 Early passage p53(-) HMEC-E6-transduced cells treated with 1.0 microM tamoxifen rapidly underwent apoptosis. Tamoxifen 70-79 tumor protein p53 Homo sapiens 14-17 11212259-5 2001 In contrast, early passage p53(+) HMEC-LXSN vector controls treated with 1.0 microM tamoxifen underwent G1-G0-phase arrest but did not undergo apoptosis. Tamoxifen 84-93 tumor protein p53 Homo sapiens 27-30 11212259-6 2001 p53(-) HMEC-E6 cells rapidly acquired resistance to tamoxifen-mediated apoptosis after 10 passages in culture (in the absence of tamoxifen). Tamoxifen 52-61 tumor protein p53 Homo sapiens 0-3 11212259-8 2001 Tamoxifen-mediated apoptosis in p53(-) HMEC-E6 cells was not blocked by inhibitors of transcription and protein synthesis. Tamoxifen 0-9 tumor protein p53 Homo sapiens 32-35 11212259-9 2001 These data suggest that the acute loss of p53 function in HMECs by expression of HPV-16 E6 results in marked sensitivity to tamoxifen-mediated apoptosis but that resistance to apoptosis rapidly develops within 10 passages in vitro. Tamoxifen 124-133 tumor protein p53 Homo sapiens 42-45 11106256-15 2000 In conclusion, we have shown that tamoxifen-stimulated T47D p53 mutant tumors can be developed rapidly with high-dose therapy (1.5 mg daily). Tamoxifen 34-43 tumor protein p53 Homo sapiens 60-63 11106256-16 2000 The results from this model provide new opportunities to investigate the rapid development of drug resistance to adjuvant tamoxifen in patients with mutant p53 breast tumors. Tamoxifen 122-131 tumor protein p53 Homo sapiens 156-159 10914720-8 2000 p53 was a significant predictor for poor cCR in the subset submitted to epirubicin (3.6 versus 25.5%; P < 0.02; in patients with p53+ and p53- BC, respectively); by contrast, only a trend toward lower cCR has been observed in patients with p53+ tumors receiving CMF +/- tamoxifen with respect to p53- ones. Tamoxifen 273-282 tumor protein p53 Homo sapiens 0-3 10661763-4 1999 In this model, TAM resistance resulted in an increase in the detectable basal levels of cyclin E, GADD 153, p16, BAX, Bcl-XL, and wild-type and mutant p53, an increase in TAM induction of p16, and a decrease in the detectable basal levels of cyclin D1, p21 and p27. Tamoxifen 15-18 tumor protein p53 Homo sapiens 151-154 9891537-10 1998 CONCLUSIONS: In this small study, tamoxifen associated tumors expressed p53 more frequently than non-users, while the opposite was observed with p21WAF1/CIP1. Tamoxifen 34-43 tumor protein p53 Homo sapiens 72-75 9891537-11 1998 This suggests that p53 mutations might play a role in development of tamoxifen associated tumors. Tamoxifen 69-78 tumor protein p53 Homo sapiens 19-22 9751262-0 1998 p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cells. Tamoxifen 80-89 tumor protein p53 Homo sapiens 0-3 9751262-2 1998 We show that the treatment of either MCF-7 (containing wild-type p53) or MDA-MB-231 cells (containing mutant p53) with tamoxifen resulted in apoptotic nuclear changes and an increase in the pre-G1 apoptotic population. Tamoxifen 119-128 tumor protein p53 Homo sapiens 65-68 9751262-2 1998 We show that the treatment of either MCF-7 (containing wild-type p53) or MDA-MB-231 cells (containing mutant p53) with tamoxifen resulted in apoptotic nuclear changes and an increase in the pre-G1 apoptotic population. Tamoxifen 119-128 tumor protein p53 Homo sapiens 109-112 9332764-2 1997 We used a case-case analysis, comparing tumors with and without overexpression of the p53 gene product to evaluate the association of putative p53 mutations with tamoxifen use and other risk factors for endometrial cancer. Tamoxifen 162-171 tumor protein p53 Homo sapiens 143-146 9553810-0 1998 Random nuclear p53 overexpression pattern in tamoxifen-mediated endometrial carcinoma. Tamoxifen 45-54 tumor protein p53 Homo sapiens 15-18 9553810-6 1998 Diffuse and intense nuclear reactivity for p53 protein was present in only one TAM-related case. Tamoxifen 79-82 tumor protein p53 Homo sapiens 43-46 9440732-0 1998 p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. Tamoxifen 51-60 tumor protein p53 Homo sapiens 0-3 9440732-3 1998 We studied whether p53 protein accumulation is a predictive factor for response to tamoxifen treatment in patients with recurrent breast cancer. Tamoxifen 83-92 tumor protein p53 Homo sapiens 19-22 9440732-8 1998 In a test for trend, we observed an association of p53 protein levels with response to tamoxifen therapy. Tamoxifen 87-96 tumor protein p53 Homo sapiens 51-54 9440732-11 1998 Also in multivariate analysis, reduced survival after the start of tamoxifen therapy was observed in the p53-high group (relative hazards rate [RHR], 1.56, 95% CI, 1.17 to 2.10; P = .002). Tamoxifen 67-76 tumor protein p53 Homo sapiens 105-108 9440732-12 1998 A statistically significant association between p53 levels and decreased tamoxifen response was seen only in the subset of patients whose tumors expressed low levels of ER or PgR (<75 fmol/mg protein). Tamoxifen 73-82 tumor protein p53 Homo sapiens 48-51 9440732-13 1998 CONCLUSION: Measurement of primary tumor p53 levels may be effective in predicting response to tamoxifen therapy in recurrent breast disease. Tamoxifen 95-104 tumor protein p53 Homo sapiens 41-44 9332764-5 1997 There was a small association between p53 overexpression and treatment with tamoxifen for breast cancer (OR = 2.6; 95% CI, 0.69-9.8). Tamoxifen 76-85 tumor protein p53 Homo sapiens 38-41 9332764-8 1997 The results suggest that use of tamoxifen may be associated with an increase in tumors that overexpress p53, although the results could be due to chance. Tamoxifen 32-41 tumor protein p53 Homo sapiens 104-107 7907850-3 1993 In this study we investigated whether tamoxifen administration affects the histopathological characteristics of cervical cancer and the expression of ER, PgR, HER-2/neu and p53 protein. Tamoxifen 38-47 tumor protein p53 Homo sapiens 173-176 9233778-3 1997 Stable Hep 3B cell lines were generated in which inducible p53 was introduced using either a temperature-sensitive mutant (p53val135) or a tamoxifen-regulated p53-estrogen receptor chimera (p53-mERtm-pBabepuro). Tamoxifen 139-148 tumor protein p53 Homo sapiens 59-62 8622078-9 1996 CONCLUSION: p53 expression appears to be indicative of clinical outcome in postmenopausal patients treated with tamoxifen. Tamoxifen 112-121 tumor protein p53 Homo sapiens 12-15 9815913-3 1995 To test the hypothesis that a p53 mutation could result in tamoxifen resistance and estrogen-independent growth, the MCF-7 cell line was transfected with p53 cDNA which was mutated at codon 179 (histidine to glutamine). Tamoxifen 59-68 tumor protein p53 Homo sapiens 30-33 9815913-4 1995 MCF-7 is an estrogen receptor-positive, estrogen-dependent, tamoxifen-sensitive cell line with only wild-type p53. Tamoxifen 60-69 tumor protein p53 Homo sapiens 110-113 9285694-5 1997 Comparatively, a treatment of the cells with 100 nM 4OH-tamoxifen (OHT) decreased cell number to 40% of the control without a concomitant decrease in the p53 levels suggesting a differential ability of these antiestrogens to regulate p53 levels in cells cultured in whole serum. Tamoxifen 67-70 tumor protein p53 Homo sapiens 154-157 9285694-5 1997 Comparatively, a treatment of the cells with 100 nM 4OH-tamoxifen (OHT) decreased cell number to 40% of the control without a concomitant decrease in the p53 levels suggesting a differential ability of these antiestrogens to regulate p53 levels in cells cultured in whole serum. Tamoxifen 67-70 tumor protein p53 Homo sapiens 234-237 9164202-1 1997 PURPOSE: To test the hypothesis that high bcl-2 expression and accumulation of p53 protein, both of which should inhibit apoptosis, are associated with a poorer tamoxifen response and a more aggressive clinical course in estrogen receptor (ER)-positive metastatic breast cancer. Tamoxifen 161-170 tumor protein p53 Homo sapiens 79-82 9042218-3 1996 The regulatory and controlling influence of Tamoxifen on numerous genes involved in apoptosis (p53, Bcl 2, c-myc, erb-B2 and others) will be discussed in this review. Tamoxifen 44-53 tumor protein p53 Homo sapiens 95-98 9816318-0 1996 Alteration of p53 damage response by tamoxifen treatment. Tamoxifen 37-46 tumor protein p53 Homo sapiens 14-17 34681897-12 2021 Cotreatment with tamoxifen, an estrogen receptor inhibitor, increased the sensitivity to doxorubicin, which decreased the colony formation of P53(+) U2OS cells. Tamoxifen 17-26 tumor protein p53 Homo sapiens 142-145 34821461-4 2022 Moreover, the generation of tamoxifen resistance involved in apoptosis escape via a reactive oxygen species-regulated p53 signaling pathway. Tamoxifen 28-37 tumor protein p53 Homo sapiens 118-121 34779146-7 2021 Impaired EPR in TP53-mutated breast cancer cases was independent from the Oncotype DX Recurrence Score group and was seen both with tamoxifen- and aromatase inhibitor-based pET (p = 0.0005 each). Tamoxifen 132-141 tumor protein p53 Homo sapiens 16-20 34681897-13 2021 Cell cycle arrest in the S phase was observed in P53(+) U2OS cells cotreated with low doses of doxorubicin and tamoxifen, while increased levels of apoptosis factors indicated cell death. Tamoxifen 111-120 tumor protein p53 Homo sapiens 49-52 34073371-0 2021 TNFalpha Enhances Tamoxifen Sensitivity through Dissociation of ERalpha-p53-NCOR1 Complexes in ERalpha-Positive Breast Cancer. Tamoxifen 18-27 tumor protein p53 Homo sapiens 72-75